Get the Stockscreener App
1.20
1.64%
-0.02
After Hours:
1.19
-0.01
-0.83%
Inmune Bio Inc stock is traded at $1.20, with a volume of 223.57K.
It is down -1.64% in the last 24 hours and down -10.45% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.22
Open:
$1.2
24h Volume:
223.57K
Relative Volume:
0.52
Market Cap:
$31.90M
Revenue:
$50,000
Net Income/Loss:
$-49.89M
P/E Ratio:
-0.5608
EPS:
-2.1398
Net Cash Flow:
$-31.55M
1W Performance:
-1.64%
1M Performance:
-10.45%
6M Performance:
-40.30%
1Y Performance:
-84.48%
1-Day Range:
$1.18
$1.23
1-Week Range:
$1.15
$1.2913
52-Week Range:
$1.15
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.20 | 32.43M | 50,000 | -49.89M | -31.55M | -2.1398 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on ... - Bluefield Daily Telegraph
INmune Bio will discuss 2025 results and corporate update March 30 - Stock Titan
INmune Bio Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Market Moves: Whats the RSI of INmune Bio Inc stock2026 Buyback Activity & Low Drawdown Investment Ideas - baoquankhu1.vn
If You Invested $1,000 in Inmune Bio Inc (INMB) - Stock Titan
Block Trades: How does INmune Bio Inc compare to its peersMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
INMB PE Ratio & Valuation, Is INMB Overvalued - Intellectia AI
INMB Showcases Advancements in Alzheimer's Treatment at AD/PD 20 - GuruFocus
INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s - TipRanks
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease - The Manila Times
Alzheimer’s trial gets plenary spotlight as blood markers guide treatment - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Rally Mode: Whats the profit margin of INmune Bio IncTrade Exit Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Earnings Beat: Is Berto Acquisition Corp Debt Equity Composite Units forming a breakout pattern2026 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Setup Watch: How liquid is INmune Bio Inc stockTrade Entry Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Will INmune Bio Inc benefit from geopolitical trends2026 Momentum & Free Community Supported Trade Ideas - baoquankhu1.vn
INmune Bio Inc Stock (ISIN: US45764T1060) Faces Analyst Hold Consensus Amid $8 Price Target - AD HOC NEWS
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades INmune Bio (INMB) - MSN
INMB Stock Receives Major Upgrade from Lucid Capital Markets | I - GuruFocus
Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com Australia
Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy By Investing.com - Investing.com India
INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of “Reduce” by Analysts - Defense World
INMB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sentiment Watch: Whats the RSI of INmune Bio Inc stockBreakout Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Breakout Zone: Is INmune Bio Inc stock undervalued right nowMarket Movers & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: What is the earnings history of INmune Bio IncJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Aug Intraday: Is CRBG undervalued by DCF analysisWeekly Earnings Recap & Weekly Momentum Picks - baoquankhu1.vn
Inmune Bio (INMB): Why This Beaten-Down Small-Cap Is Back on Risk Radars - AD HOC NEWS
INMB Technical Analysis & ETF Price Forecast - Intellectia AI
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next - TipRanks
INmune Bio Highlights CORDStrom RDEB Program and IP Strength - TipRanks
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Inmune Bio, Inc. advances therapies for rare disease impact beyond skin - Traders Union
INmune Bio Announces Upcoming Webinar on New RDEB Treatment Data - National Today
INMB.O Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Decliners: What is the earnings history of INmune Bio IncJuly 2025 Big Picture & Expert Verified Stock Movement Alerts - baoquankhu1.vn
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study - TipRanks
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - The Manila Times
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Levels Update: Is INmune Bio Inc stock undervalued right nowMarket Sentiment Review & Daily Stock Trend Reports - baoquankhu1.vn
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - The Manila Times
INmune Bio to host webinar on RDEB treatment data - Investing.com Australia
INmune Bio to Present New CORDStrom Phase III Data - TipRanks
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
CORDStrom Phase III RDEB data to be detailed by INmune Bio (NASDAQ: INMB) - Stock Titan
INmune Bio to host webinar on RDEB treatment data By Investing.com - Investing.com Nigeria
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):